Elizabeth Cunningham, APRN
Psychiatric/Mental Health · Spartanburg, SCNPI 1225627490
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 24.1% of the total.
Across 238 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$934
- Otsuka America Pharmaceutical, Inc.$472
- Neurocrine Biosciences, Inc.$458
- AbbVie$438
- Vanda Pharmaceuticals Inc.$276
- E.r. Squibb & Sons, L.L.C.$244
- plus $1K from 9 others
What the payments were for
- Food & beverage$3,76297%
- Education$1133%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 53 | $934 |
| Otsuka America Pharmaceutical, Inc. | 36 | $472 |
| Neurocrine Biosciences, Inc. | 23 | $458 |
| AbbVie | 41 | $438 |
| Vanda Pharmaceuticals Inc. | 13 | $276 |
| E.r. Squibb & Sons, L.L.C. | 13 | $244 |
| Johnson & Johnson | 14 | $220 |
| Alkermes, Inc. | 11 | $210 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $175 |
| Sunovion Pharmaceuticals Inc. | 8 | $135 |
| Indivior Inc. | 8 | $109 |
| Lundbeck LLC | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Corium, LLC | 2 | $43 |
| Axsome Therapeutics, Inc. | 1 | $28 |
How this compares
$3,874 in reported general payments places this provider in the 85th percentile of 354 psychiatric/mental health providers in South Carolina.
See all psychiatric/mental health providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 34 | $308,817 |
| IngrezzaValbenazine Tosylate | 37 | $308,684 |
| Invega SustennaPaliperidone Palmitate | 76 | $252,227 |
| Invega TrinzaPaliperidone Palmitate | 18 | $133,344 |
| VraylarCariprazine Hcl | 44 | $67,269 |
| Abilify MaintenaAripiprazole | 23 | $66,437 |
| RexultiBrexpiprazole | 16 | $37,773 |
| TrintellixVortioxetine Hydrobromide | 34 | $17,623 |
| Aripiprazole | 96 | $14,216 |
| Paliperidone ErPaliperidone | 63 | $9,339 |
| Olanzapine | 185 | $3,695 |
| Quetiapine Fumarate | 187 | $2,973 |
| Divalproex Sodium ErDivalproex Sodium | 45 | $2,655 |
| Benztropine Mesylate | 186 | $2,319 |
| Fluvoxamine Maleate | 29 | $2,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $220 | $385,57194 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $934 | $308,81734 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $458 | $308,68437 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $472 | $104,21039 claims |
| AbbVieVraylar | $438 | $67,26944 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $48 | $17,62334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 354 psychiatric/mental health providers in South Carolina.
Other psychiatric/mental health in Spartanburg
- Kristen KlimbalSpartanburg$6K
- Steven KrozerGreenville$139K
- Luron FlemingGreenville$61K
- Cerrissa HugieCharleston$54K
- Karen FulwoodMyrtle Beach$30K
- Taylor CrewsIsle Of Palms$28K
- Lauren DyerGreenville$16K
- Melissa BrownGreenville$16K
- Mary McManusNorth Myrtle Beach$15K
- Kelsie FowlerAnderson$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.